Borderline lepromatous leprosy (Q95184): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Changed an Item
‎Changed an Item
 
(3 intermediate revisions by the same user not shown)
Property / Canary Token
 
dki-india-ID_1888276943
Property / Canary Token: dki-india-ID_1888276943 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
15 August 2026
Timestamp+2026-08-15T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 15 August 2026 / rank
 
Normal rank

Latest revision as of 10:54, 16 August 2026

Borderline lepromatous (BL) leprosy is similar to lepromatous leprosy but the presence of some cell-mediated immune response to infection prevents the unfettered proliferation of bacilli in the skin. It is characterised by large numbers of poorly-defined macules, papules and plaques with a tendency to be distributed symmetrically. Neuropathy tends to be of a diffuse "glove and stocking" type. Initiation of treatment, however, may be accompanied by recovery of cell-mediated immunity and a risk of severe nerve damage (upgrading reaction/Type I reaction) [Dermatology TAG].
Language Label Description Also known as
default for all languages
ID_1888276943
    English
    Borderline lepromatous leprosy
    Borderline lepromatous (BL) leprosy is similar to lepromatous leprosy but the presence of some cell-mediated immune response to infection prevents the unfettered proliferation of bacilli in the skin. It is characterised by large numbers of poorly-defined macules, papules and plaques with a tendency to be distributed symmetrically. Neuropathy tends to be of a diffuse "glove and stocking" type. Initiation of treatment, however, may be accompanied by recovery of cell-mediated immunity and a risk of severe nerve damage (upgrading reaction/Type I reaction) [Dermatology TAG].

      Statements

      CID11:ID_1888276943
      0 references
      dki-india-ID_1888276943
      0 references
      Concluído
      0 references
      15 August 2026
      0 references